PDMR Dealing and ESOT Share Purchase

Cellbxhealth PLC

19 December 2025

 

CELLBXHEALTH plc ("the Company")

DIRECTOR/PDMR SHAREHOLDING AND ESOT SHARE PURCHASE

Guildford, UK - 19 December 2025 - CELLBXHEALTH plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology,  announces that, following the Oversubscribed Placing and Subscription announced on the 25 November 2025, Executive Chairman, Jan Groen and Chief Executive Officer Peter Collins each acquired 5,000,000 Ordinary Shares in the Company. In addition, Sinead Armstrong, Finance Director acquired 2,500,000 Ordinary Shares in the Company.  All shares were purchased at a price of 1.0 pence, being the Placing Price.

Following the transaction, Dr Groen's and Mr Collins' aggregate direct and indirect ultimate beneficial interest in the Company's Ordinary Shares is 5,000,000 representing approximately 0.4% of the Company's currently issued share capital, Mrs Armstrong's aggregate direct and indirect ultimate beneficial interest in the Company's Ordinary Shares is 2,596,056 representing approximately 0.2% of the Company's currently issued share capital.

Employee Share Ownership Trust Share Purchase

Furthermore, the Company announces that Zedra Trust Company (Guernsey) Ltd, acting as trustee of the ANGLE Employee Share Ownership Trust (the "ESOT"), purchased, earlier today, a total of 2,886,742 ordinary shares in the Company at a price of 1.1p each.

 The shares will be held in the ESOT, which is a discretionary trust for the benefit of the Company's employees and will ultimately be used to satisfy share awards and options granted under the Company's various share incentive arrangements.

The ESOT may be used to assist in meeting the obligations under employee remuneration schemes with Executive Directors and Persons Discharging Managerial Responsibility of the Company, together with other employees, as potential beneficiaries and are therefore treated as having an interest in some of those shares and the dealings thereof.

 Immediately following settlement of the above transaction, the ESOT will hold 3,000,000 ordinary shares ("ESOT Shares") representing 0.3% of the Company's issued share capital.

 The Company's issued share capital as at 19 December 2025 consists of 1,139,402,658 ordinary shares of 0.05 pence each with voting rights. The Company does not hold any shares in treasury and has waived its right to exercise its voting rights and to receive dividends in respect of the EBT Shares. Therefore, the total number of voting rights is 1,136,402,658.

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Announcement on 24 November 2025.

For further information:

CelLBxHealth plc	[phone]
Peter Collins, Chief Executive Officer Jan Groen, Executive Chairman	[e-mail]
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales)	[phone]
FTI Consulting Simon Conway, Ciara Martin, Sam Purewal	[phone]

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Notes for editors 

About CelLBxHealth plc

CelLBxHealth plc is a precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Laboratory services: Clinical trial support and assay development (3) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme.

 The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP certified UK laboratory, providing bespoke clinical-trial support and assay development. 

For more information, visit https://cellbxhealth.com/.

The Company's LEI is 213800BY11K6W3NMS374

 This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities ("PDMR") and persons closely associated with them ("PCA")

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail in respect of the transaction as described above.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	a)   Jan Groen b)   Peter Collins c)   Sinéad Armstrong
2	Reason for the notification
a)	Position/status	a)   Jan Groen (Chairman) b)   Peter Collins (CEO) c)   Sinéad Armstrong (FD)
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	CelLBxHealth Plc
b)	LEI	213800BY11K6W3NMS374
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 0.05 pence value each
	Identification code	GB0034330679
b)	Nature of the transaction	a)   Jan Groen - Purchased 5,000,000 Ordinary Shares b)   Peter Collins - Purchased 5,000,000 Ordinary Shares c)   Sinead Armstrong - Purchased 2,500,000 Ordinary Shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			a)   1p b)   1p c)   1p	a)   5,000,000 b)   5,000,000 c)   2,500,000
d)	Aggregated information
	- Aggregated volume	n/a, each a single transaction
	- Price	n/a, each a single transaction
e)	Date of the transaction	18 December 2025
f)	Place of the transaction	AIM

 

END